BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kohles N, Nagel D, Jüngst D, Durner J, Stieber P, Holdenrieder S. Relevance of circulating nucleosomes and oncological biomarkers for predicting response to transarterial chemoembolization therapy in liver cancer patients. BMC Cancer. 2011;11:202. [PMID: 21615953 DOI: 10.1186/1471-2407-11-202] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Stoetzer OJ, Wittwer C, Lehner J, Fahmueller YN, Kohles N, Fersching DM, Leszinski G, Roessner J, Holdenrieder S. Circulating nucleosomes and biomarkers of immunogenic cell death as predictive and prognostic markers in cancer patients undergoing cytotoxic therapy. Expert Opin Biol Ther 2012;12 Suppl 1:S217-24. [PMID: 22620489 DOI: 10.1517/14712598.2012.689280] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
2 Kohles N, Nagel D, Jüngst D, Durner J, Stieber P, Holdenrieder S. Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy. Tumour Biol. 2012;33:33-40. [PMID: 21931992 DOI: 10.1007/s13277-011-0237-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
3 Fako V, Wang XW. The status of transarterial chemoembolization treatment in the era of precision oncology. Hepat Oncol 2017;4:55-63. [PMID: 28989699 DOI: 10.2217/hep-2017-0009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
4 Wang L, Yao M, Dong Z, Zhang Y, Yao D. Circulating specific biomarkers in diagnosis of hepatocellular carcinoma and its metastasis monitoring. Tumour Biol. 2014;35:9-20. [PMID: 24006223 DOI: 10.1007/s13277-013-1141-0] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 4.9] [Reference Citation Analysis]
5 Zhou J, Shi YH, Fan J. Circulating cell-free nucleic acids: promising biomarkers of hepatocellular carcinoma. Semin Oncol 2012;39:440-8. [PMID: 22846861 DOI: 10.1053/j.seminoncol.2012.05.013] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
6 Handke NA, Rupp ABA, Trimpop N, von Pawel J, Holdenrieder S. Soluble High Mobility Group Box 1 (HMGB1) Is a Promising Biomarker for Prediction of Therapy Response and Prognosis in Advanced Lung Cancer Patients. Diagnostics (Basel) 2021;11:356. [PMID: 33672622 DOI: 10.3390/diagnostics11020356] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Tampaki M, Doumba PP, Deutsch M, Koskinas J. Circulating biomarkers of hepatocellular carcinoma response after locoregional treatments: New insights. World J Hepatol 2015; 7(14): 1834-1842 [PMID: 26207165 DOI: 10.4254/wjh.v7.i14.1834] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
8 Wittwer C, Boeck S, Heinemann V, Haas M, Stieber P, Nagel D, Holdenrieder S. Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy. Int J Cancer. 2013;133:2619-2630. [PMID: 23729200 DOI: 10.1002/ijc.28294] [Cited by in Crossref: 20] [Cited by in F6Publishing: 34] [Article Influence: 2.2] [Reference Citation Analysis]
9 Stoetzer OJ, Fersching DM, Salat C, Steinkohl O, Gabka CJ, Hamann U, Braun M, Feller A, Heinemann V, Siegele B, Nagel D, Holdenrieder S. Prediction of response to neoadjuvant chemotherapy in breast cancer patients by circulating apoptotic biomarkers nucleosomes, DNAse, cytokeratin-18 fragments and survivin. Cancer Letters 2013;336:140-8. [DOI: 10.1016/j.canlet.2013.04.013] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
10 Wang Y, Chen Y, Ge N, Zhang L, Xie X, Zhang J, Chen R, Wang Y, Zhang B, Xia J. Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization. Ann Surg Oncol. 2012;19:3540-3546. [PMID: 22532305 DOI: 10.1245/s10434-012-2368-5] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
11 Lin YM, Taiji R, Calandri M, Odisio BC. Tumor Biomarkers and Interventional Oncology: Impact on Local Outcomes for Liver and Lung Malignancy. Curr Oncol Rep 2021;23:67. [PMID: 33855606 DOI: 10.1007/s11912-021-01056-4] [Reference Citation Analysis]
12 Peng Z, Cao G, Hou Q, Li L, Ying S, Sun J, Zhou G, Zhou J, Zhang X, Ji W, Yu Z, Li T, Zhu D, Hu W, Ji J, Du H, Shi C, Guo X, Fang J, Han J, Gu W, Xie X, Sun Z, Xu H, Wu X, Hu T, Huang J, Hu H, Zheng J, Luo J, Chen Y, Yu W, Shao G. The Comprehensive Analysis of Efficacy and Safety of CalliSpheres® Drug-Eluting Beads Transarterial Chemoembolization in 367 Liver Cancer Patients: A Multiple-Center, Cohort Study. Oncol Res 2020;28:249-71. [PMID: 31856933 DOI: 10.3727/096504019X15766663541105] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
13 García-muñoz A, Bologna-molina R, Aldape-barrios B, Licéaga-escalera C, Montoya-pérez LA, Rodríguez MA. Identification of Proteins With Increased Levels in Ameloblastic Carcinoma. Journal of Oral and Maxillofacial Surgery 2014;72:1183-96. [DOI: 10.1016/j.joms.2013.11.029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
14 Oklu R, Sheth RA, Wong KHK, Jahromi AH, Albadawi H. Neutrophil extracellular traps are increased in cancer patients but does not associate with venous thrombosis. Cardiovasc Diagn Ther 2017;7:S140-9. [PMID: 29399517 DOI: 10.21037/cdt.2017.08.01] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
15 Zhu K, Dai Z, Zhou J. Biomarkers for hepatocellular carcinoma: progression in early diagnosis, prognosis, and personalized therapy. Biomark Res. 2013;1:10. [PMID: 24252133 DOI: 10.1186/2050-7771-1-10] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 4.7] [Reference Citation Analysis]
16 Kohles N, Nagel D, Jüngst D, Stieber P, Holdenrieder S. Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy. Tumour Biol. 2012;33:2401-2409. [PMID: 22965881 DOI: 10.1007/s13277-012-0504-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
17 Krishnamurthy K, Febres-Aldana CA, Imperatore K, Sriganeshan V, Poppiti R. Neutrophil extracellular traps and NETosis: a report of two autopsies and review of literature. Blood Coagul Fibrinolysis 2020;31:92-6. [PMID: 31789662 DOI: 10.1097/MBC.0000000000000872] [Reference Citation Analysis]